Patents by Inventor David Colcher

David Colcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TAG72 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF TAG72-POSITIVE TUMORS
    Publication number: 20210308184
    Abstract: Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described
    Type: Application
    Filed: August 1, 2019
    Publication date: October 7, 2021
    Inventors: Saul J. Priceman, John P. Murad, Stephen J. Forman, Jack Shively, Paul Yazaki, David Colcher, Anna Kozlowska, Hee Jun Lee
  • Radioprotectant for peptides labeled with radioisotope
    Patent number: 6338835
    Abstract: A method of ameliorating degradation radiolabeled peptides, especially radiolabeled proteins such as antibodies, by including povidone, also widely known as polyvinylpyrrolidone or PVP, as a radioprotectant in a composition containing a radiolabeled peptide is described. A radioprotectant composition and a stable peptide-radioisotope composition having povidone are also described. Ascorbic acid or other secondary stabilizers may also be added to the compositions to further enhance radioprotection.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: January 15, 2002
    Assignee: Coulter Pharmaceutical, Inc.
    Inventors: Dan Shochat, Albert S. K. Chan, Michael J. Buckley, David Colcher
  • Radioprotectant for peptides labeled with radioisotope
    Patent number: 5961955
    Abstract: A method of ameliorating degradation of radiolabeled peptides, especially radiolabeled proteins such as antibodies, by including povidone, also widely known as polyvinylpyrrolidone or PVP, as a radioprotectant in a composition containing a radiolabeled peptide is described. A radioprotectant composition and a stable peptide-radioisotope composition having povidone are also described. Ascorbic acid or other secondary stabilizers may also be added to the compositions to further enhance radioprotection.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: October 5, 1999
    Assignee: Coulter Pharmaceutical, Inc.
    Inventors: Dan Shochat, Albert S. K. Chan, Michael J. Buckley, David Colcher
  • Second generation monoclonal antibodies having binding specificity to TAG-72 and human carcinomas and methods for employing the same
    Patent number: 5512443
    Abstract: The present invention relates to second generation monoclonal antibodies having binding specificity to a tumor associated glycoprotein having an approximate molecular weight of >10.sup.6 d ("TAG-72") and human carcinomas and methods for employing the same. Hybridomas producing such antibodies have been prepared.
    Type: Grant
    Filed: July 2, 1990
    Date of Patent: April 30, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey Schlom, David Colcher
  • Monoclonal antibodies reactive with human breast cancer
    Patent number: 4612282
    Abstract: Monoclonal antibodies demonstrating a reactivity with human breast cancer are produced. The hybridoma cultures secreting immunoglobins are produced by hydridoma technology. Splenic lymphocytes of mice, immunized with membrane-enriched fractions of metastatic human mammary carcinoma tissue are fused with the NS-1 non-immunoglobulin-secreting murine myeloma cell line. Screening of immunoglobulin reactivities and double cloning of cultures yielded 11 monoclonal antibodies that demonstrated activities with the surface of human mammary tumor cells and not with the surface of apparently normal human tissues. These monoclonal antibodies aid in the diagnosis, prognosis and treatment of human breast cancer.
    Type: Grant
    Filed: March 1, 1985
    Date of Patent: September 16, 1986
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jeffrey Schlom, David Colcher, Marianna Nuti, Patricia H. Hand, Faye Austin
  • Process for producing monoclonal antibodies reactive with human breast cancer
    Patent number: 4522918
    Abstract: Monoclonal antibodies demonstrating a reactivity with human breast cancer are produced. The hybridoma cultures secreting immunoglobins are produced by hydridoma technology. Splenic lymphocytes of mice, immunized with membrane-enriched fractions of metastatic human mammary carcinoma tissue are fused with the NS-1 non-immunoglobulin-secreting murine myeloma cell line. Screening of immunoglobulin reactivities and double cloning of cultures yielded 11 monoclonal antibodies that demonstrated activities with the surface of human mammary tumor cells and not with the surface of apparently normal human tissues. These monoclonal antibodies aid in the diagnosis, prognosis and treatment of human breast cancer.
    Type: Grant
    Filed: December 15, 1981
    Date of Patent: June 11, 1985
    Inventors: Jeffery Schlom, David Colcher, Marianna Nuti, Patricia H. Hand, Faye Austin